Indeed, PARPi in combination with STING agonists demonstrated superior anti-tumor efficacy than PARPi combined with macrophage depletion via anti-CSF1R in our syngeneic GEMM of Brca1-deficient breast cancers. Here, CSF1R is linked to breast carcinoma.